Modified FOLFIRINOX
7 clinical trials
4 abstracts
6 indications
Indication
Pancreatic Ductal AdenocarcinomaIndication
Pancreatic CancerIndication
Colon Cancer Stage IIIIndication
Pancreatic adenocarcinomaIndication
Pancreatic AdenocarcinomaAbstract
GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.Org: Chirurgia Digestiva, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Wallace McCain Center for Pancreatic Cancer,
Abstract
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial.Org: Amsterdam UMC Location University of Amsterdam, University Hospital Essen West German Cancer Center,
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Clinical trial
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical ResectionStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 2 Study of Neoadjuvant NIS793 in Combination With mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PDAC)Status: Terminated, Estimated PCD: 2023-08-16
Clinical trial
mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II StudyStatus: , Estimated PCD: 2025-03-15
Clinical trial
Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Multicenter Open-Label Dose Optimization Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the PancreasStatus: Withdrawn, Estimated PCD: 2027-01-01
Clinical trial
Randomized Phase 2 Study of mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Patients With Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-08-14
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,